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Foreword
In most countries, people who are dependent on drugs are stigmatized and excluded
from mainstream society. But these people should not be shut out. That will only
exacerbate the problem. They should be helped through treatment. It is the only way
to get them back into society, free of addiction. 
In a sense, a rise in the number of people seeking treatment is a good sign. While it
is a leading indicator of drug abuse, it is also a cry for help. And that is the first step
towards overcoming drug dependence. 
It is therefore essential that when people seek treatment, they find proper care.
Without it, they risk further drug dependence and social isolation. 
Treatment relies on information. At the individual level, a health expert needs to be
informed about the profile of his subject in order to have a clear picture of his/her
problem and to design the treatment and rehabilitation accordingly. 
More generally, the data collected contributes to our greater understanding of trends
and patterns of drug dependency, which can increase our understanding of the nature
and the extent of the problem and, as a result, improve the impact and efficiency of
treatment services.
In order to assist countries enhance their drug abuse information systems, the United
Nations Office on Drugs and Crime, the European Monitoring Centre for Drugs and
Drug Addiction, together with experts from other international organizations and
national drug information systems, have produced this Toolkit Module 8—Guidance for
the measurement of drug treatment demand. This module, building also on the Joint
Pompidou Group—EMCDDA Treatment Demand Indicator Protocol, provides experts
and practitioners in the field of treatment services with concrete guidelines for estab-
lishing and managing systems for the collection of treatment demand data. 
The aim is to improve common standards for data collection and monitoring. This
should enable a more uniform approach around the world, provide a clearer picture
of drug trends and facilitate comparative analysis. The evidence that is collected should
improve our capacity to measure drug treatment demand and respond accordingly
with effective demand reduction programmes and projects. 
This a shared interest of the European Monitoring Centre for Drugs and Drug
Addiction and the United Nations Office on Drugs and Crime, which are mandated
by our respective member States and governing bodies to collect and analyse infor-
mation on the drug problem. We hope that this latest joint project will contribute to
improving the analysis of the drug situation and help to identify effective approaches
to drug treatment and rehabilitation.
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A. Aim
Although data on demand for drug abuse treatment are commonly
available in many countries, there is an overall lack of standardiza-
tion with regard to data coverage, concepts, methods and tools, which
makes cross-national comparisons and identification of client charac-
teristics and their needs in different national and regional settings
very difficult. In order to assist countries in compiling comparable
data on drug treatment demand, the present Treatment Demand
Indicator (TDI) Global Toolkit has been prepared for inclusion as
Module 8 of the Epidemiological Toolkit of the Global Assessment
Programme on Drug Abuse (GAP) of the United Nations Office on
Drugs and Crime (UNODC). The module has been developed in
collaboration with the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA), building on the work of the Pompidou
Group and incorporating the experience of major ongoing treatment
information systems.
GAP improves the global information base on patterns and trends in
drug consumption by helping Member States to build the systems
necessary for collecting reliable data to inform policy and action;
encouraging sharing of experience and technical developments
through regional partnerships; and encouraging the adoption of sound
methods to collect comparable data.
The GAP Epidemiological Toolkit is intended to help States Members
of the United Nations to develop drug information systems that are
culturally appropriate and relevant, to ensure that existing drug infor-
mation systems conform to internationally recognized standards of
good practice and to focus on the harmonization of drug abuse indi-
cators. Other modules provide support in the following areas:
 Development of an integrated drug information system
 Indirect prevalence estimation techniques
 School surveys
 Data interpretation and management for policy formation
 Basic data analysis using a statistical software package for the social sciences
 Focus assessment studies using qualitative research methods
 Ethical issues
Other GAP activities include providing technical and financial support to establish
drug information systems and support for and coordination of global data collection
activities. For further information on GAP Epidemiological Toolkit modules, contact
GAP by electronic mail (e-mail) at gap@unodc.org, visit the website of the UNODC
at www.unodc.org or contact the Office at P.O. Box 500, 1400 Vienna, Austria.
For further information on EMCDDA TDI methodology and results please consult
the following website: http://www.emcdda.eu.int/?nnodeid=1420.
B. General approach
In order to implement an information system for drugs, it is essential to approach the
issue both from an operational perspective and from an organizational perspective. 
1. Operational perspective
This is the ground level, practical or “bottom-up” approach, in which treatment
providers, agencies and services are helped to understand the need for and value of
such a system, are signed up to the initiative and become committed to it because
they can perceive its value and utility.
2
GAP Toolkit Module 8 Guidance for the measurement of drug treatment demand
Building your
foundation
Data issues Implementation
Analysis and
reporting
Maintenance and
evaluation
Operational
commitment
Organizational
commitment
2. Organizational perspective
This is the “top-down” or political approach, in which key individuals and organi-
zations are either driving the initiative because of their own policy needs or are
persuaded to adopt the system for the greater good. Either way there should be the
political will for such a development that percolates down through the various
organizational tiers and allows it to happen.
3. Sequential stages
The above diagram shows the logical stages that such a development must follow
if it is to be successful. These stages correspond to chapters III-VII in the Toolkit
itself as follows:
I. Introduction
II. Reasons for collecting drug treatment data
III. Building your foundation
IV. Data issues
V. Implementation
VI. Analysis and reporting
VII. Maintenance and evaluation
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A. Why a system of treatment data collection 
is useful: main purposes
Treatment reporting systems were first introduced during the 1960s
and 1970s and many European countries developed and/or stan-
dardized systems during the 1990s [1]. In many countries, they
represent the most substantial and long-standing available source of
information about drug use.
Knowledge about the number and characteristics of drug users who
seek help and the treatment that they receive is valuable to a variety
of audiences. It must underpin the planning and management of the
treatment system and inform the commissioning of treatment services.
It may also assist with the process of need assessment, offer data for
research and provide epidemiological indicators of drug problems in
the wider community. Ultimately, it should be part of the evidence
base within a national information system, to inform and develop
drug policy.
1. Epidemiological purposes
Information concerning people treated for drug problems is very use-
ful for epidemiologists, who undoubtedly benefit from systematically
collected drug treatment data in better understanding the drug
problem, its extent, patterns and trends. Such data collection must
be systematic, in particular because data need to be compiled from
a number of different types of facility providing drug treatment
services. Disease registries are an established feature of research in
other areas of epidemiology and properly designed treatment sur-
veillance systems should serve a similar function in drug misuse
epidemiology.
Treated drug users represent a visible part of the, often elusive, pop-
ulation that experiences problems associated with drug use. As such,
information about identified cases might provide a “window” onto an
otherwise hidden drug problem. It might indicate what sections of
the population are most affected by drug problems, the types of problem that are
experienced and the levels of associated morbidity. Most important, it should provide
information to answer questions about the level of treatment demand and patterns
of service utilization.
Where privacy legislation permits, it is advantageous if treatment data can allow
case linkage. This will reduce the extent of multiple counting in situations where
drug users may be known to multiple services. It may also enable case linkage with
recording systems that monitor drug users’ other institutional contacts. For example,
it may facilitate longitudinal tracking of clients between the health and criminal
justice system and can enable other methodologies such as capture-recapture to be
applied to data from the system. In many countries treatment data include details
of clients’ initials, date of birth and gender, referred to as an “attributor” code [2],
which are suitable for the purposes of case linkage.
For identifying patterns of drug use
In many countries where these data have not previously been collected, it will be
valuable to establish basic patterns of drug use in the first instance. Such infor-
mation will include the drugs most commonly reported, their route of use and the
age groups mainly affected—information that has not hitherto been available. The
importance of such basic information should not be underestimated. As the systems
become more sophisticated, more detailed and specific data collection and research
questions can be implemented. 
As an indirect indicator of trends in problem drug use
Drug users’ behaviour may often attract social and legal sanctions; hence, the
population that experiences drug problems is often elusive, or “hidden”. As a result,
it is usually necessary to rely on indirect indicators of underlying changes in that
population. Where information is collected systematically and case and data
definitions are held constant over time, treatment data may provide one such 
indirect indicator.
Changes in the size or composition of the population that seeks help may indicate
changes in the size or composition of the population experiencing drug problems.
For example, an increase in the use of stimulants might be reflected in increasing
numbers of stimulant users seeking help. It is helpful if data collection can identify
cases that have sought treatment for the very first time (first treatment demand), 
as these may sometimes be most representative of the underlying, untreated
population. An increase in the number of first demands for treatment may 
indicate that the incidence of drug problems has increased. The appearance of new
drugs of misuse, new routes of administration or a change in the characteristics of
a particular subgroup may indicate that changes have taken place in the untreated
population.
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It is essential, however, to remember the service-dependent nature of treatment data,
as changing patterns among the treated population may be a consequence of changes
in the pattern of service provision, rather than of changes in the underlying
population. 
As a basis for other methodologies
A treatment surveillance system may provide ready access to data suitable for esti-
mation methodologies. For example, where data items suitable for case linkage are
collected, it can provide samples for use in capture-recapture prevalence studies.
Capture-recapture ascertains the extent to which lists of known cases have been
sampled from an underlying population. It does this by comparing the overlap
between known samples and, on that basis, estimates the size of the unsampled
part of the population. The method is recommended by EMCDDA as a method to
obtain prevalence estimates at the local level [3] and has been applied in numer-
ous studies of drug use prevalence [4-35]. Although its use in epidemiology has
been criticized [36], it is a well-tried and efficient method of obtaining useful and
credible estimates of the prevalence of problem drug use.
Where time-series data about persons seeking treatment are available, these may
provide a suitable basis on which to generate indicators of the incidence of certain
types of drug use within the population. Using lag-correction techniques, it is
possible to produce indicators of incidence trends within the population, account-
ing for those who have not yet sought help for their drug problem [37-39]. Lag-
correction combines information about observed incidence among diagnosed cases
with information about the observed delay between onset and diagnosis in order to
produce incidence estimates for those who have not yet sought help. 
Management purposes
Those responsible for planning, managing and commissioning treatment services
need to be able to assess the performance of those services. A treatment surveil-
lance system can provide an objective and external source of information that enables
comparison between similar types of service and monitoring of changes in service
performance over time.
As national understanding of the need for drug services develops, it is likely that
national and local targets will be set and figures evaluated against these targets.
(See, for example, local delivery plans and public service agreements for England at
http://www.ndtms.net/LocalDeliveryPlan.aspx and http://www.ndtms.net.)
Performance management is likely to require an information system that can pro-
vide more detailed information about the treatment process and its outcomes, in
order to answer such questions as: How long do clients wait before treatment com-
mences? How long does the treatment last? In what situation are the clients when
the treatment is completed?
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Perhaps the most fundamental question in performance management concerns the
degree to which treatment agencies engage with, and retain, their target population.
Used in conjunction with other sources of information, treatment data may answer
such fundamental questions. For example, where methods such as capture-recapture
(see below) have been applied to obtain prevalence estimates, these may be com-
bined with information about the size of the population that accesses services to
provide a public health indicator of coverage by services of their target population
[32,40].
For policy and advocacy
Information about persons with known drug problems may provide essential infor-
mation for policymakers to take broad decisions about the need for prevention inter-
ventions, treatment services, ongoing aftercare and control.
To identify patterns of use of services
Once the system is fully up and running, and when it is possible to combine treat-
ment demand data with other national data sets, it should be possible to identify
shortfalls in service provision across a geographical/organizational area.
For service evaluation
Countries will find that data from treatment information systems are much in
demand for a range of research and evaluative work around treatment uptake,
retention and effectiveness.
Other purposes
These include providing information for students, the media and general public.
To be useful for any of these, data collection must be systematic. It should involve
case and data definitions that are consistent between agencies, geographical regions
and over time. Without consistent systematic data collection, there are severe
problems in combining the information gathered by different agencies even at the
city or regional levels. Such problems are amplified at the national and international
levels. Furthermore, if case and data definitions are subject to frequent change, then
soon it becomes difficult to discern trends in the information that is available.
When systematic data collection and aggregation are routine, they provide a central
reference point for those needing to investigate treatment data and allow consistent
publication of aggregate statistics. Although the level of detail required by the var-
ious audiences for treatment information will differ, a skillfully designed system
should provide a cost-effective way of pooling the information that most, if not all,
treatment agencies will already gather for clinical management and accountability
purposes.
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B. Limitations
Some limitations of treatment data should be recognized. Firstly, the data will be
affected by the degree to which agencies comply with data requirements. Even where
there is a legal requirement to contribute data, health professionals have not always
been willing to comply with that requirement [41]. Where compliance rests on good-
will alone, it is inevitable that treatment systems will under-record. In some
circumstances, under-reporting may simply be a consequence of administrative
burden or a change in key personnel. In others, there may be a basic unwillingness
on the part of an agency to open its treatment activities to external scrutiny, or
concern about the possible disclosure of patient information. In either case, it is
desirable that mechanisms to audit reporting completeness are put in place so 
as to allow the degree of under-recording to be quantified, understood and,
subsequently, minimized.
Sources of bias and external influence may sometimes place limitations on the
conclusions that can be reached. For example, as already suggested, although an
increase in the number of persons seeking treatment may indicate an increase in
prevalence, it may alternatively indicate an increase in treatment capacity or through-
put. Equally, an increase in the number of young people seeking treatment may
indicate increasing incidence of drug problems in the population, or may reflect 
a successful attempt to intervene at an earlier stage in drug users’ “career”. The
data generated by treatment agencies are service-dependent, that is to say, as well
as reflecting the size and composition of the population that experiences drug 
problems, they also reflect the agencies’ attempts to attract that population into
therapeutic contact. 
Furthermore, because treatment agencies may cater for the needs of particular types
of client, treatment data may not capture information about specific subgroups that
arise within the population. For example, where services cater primarily for the needs
of opiate users, an increase in problematic use of cocaine within the community
may not necessarily result in increased demands for cocaine treatment.
It is also important to note that it may take some time for changes in the under-
lying population to be reflected in the treated population. For example, treatment
data may not immediately reflect changes in the incidence of use, because of the
lag between onset of use and first treatment demand. 
Definitions of the problems associated with drug use are, to a degree, socially, cul-
turally and politically, as well as medically defined. Treatment provision that is con-
cerned largely with addressing the medical consequences of addiction may access a
very different population of drug users than provision that is focused primarily on
the social or public health of a community.
Recipients of information based on drug treatment data should be made aware of
such limitations. This is most important where data are to be published in the public
9
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domain or are targeted at an audience otherwise unfamiliar with the methods. If
there is a possibility that published figures might be open to misinterpretation, then,
as far as possible, publications should highlight which conclusions may reasonably
be drawn, and which may be inappropriate.
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As a first step towards introducing a drug treatment demand infor-
mation system, it is useful to carry out a three-stage exercise in order
to establish a baseline of existing information and resources, as fol-
lows: needs assessment, organizational assessment and an inventory
of treatment facilities. This is sometimes called an information, needs
and resources assessment (INRA).*
A. Needs assessment
Sufficient time should be allocated to the following background work:
(a) Identify key stakeholders who will be the recipients of feedback
from these initial processes;
(b) Document the kind and nature of information that currently
exists on drug misuse in the country;
(c) Make an inventory of instruments collecting data;
(d) Conduct an audit of existing drug misuse studies and reports;
(e) Identify which important questions cannot be answered with
existing information;
(f) Determine the potential that exists for developing ongoing sur-
veillance and monitoring activities;
(g) Identify the resources that are to be made available to the project
along with an indication of expected timescale for development;
(h) Identify priority areas for national assessment as well as for future
data collection and document the necessary accompanying infra-
structure, technical support and training needs;
Having carried out such an audit, it will be important for key stake-
holders to analyse the information gained in three ways:
Firstly, available data sources on drug misuse are analysed
individually to assess their utility and to determine areas of
common purpose and content, where they exist, so as to
minimize duplication.
*A good example of an INRA report can be found at www.un.org.tr/unic/docs/
INRA_Turkey_Eng.pdf
Secondly, information from the analysis of data sources is assimilated with
information on available resources to form a framework for the development
of the system.
Thirdly, strategic goals are set for the development of the proposed informa-
tion system.
Once strategic goals have been set, the following tasks are recommended:
(a) Identify key individuals and institutions that are best placed to contribute to
a national drug misuse epidemiological network;
(b) Develop a coordinated information network including linkage and information-
sharing, and a reporting mechanism among the different professionals and
institutions involved in drug control;
(c) Address the issue of training for selected personnel in drug misuse epi-
demiology, especially with regard to guidelines on developing core indicators,
data management and analysis, as well as data capture at the clinical level.
(d) Address infrastructure needs such as staff provision, a skills base for the
development of templates for data collection for the indicators, provision of
database software and computers, and support.
The above section was adapted from United Nations source material [42].
B. Organizational Issues
1. Gaining political and senior management support
The need to gain political support has already been mentioned. Throughout this
development phase it is very important to involve relevant authorities at all levels.
Key personnel at the government and local government levels, as well as senior
executives of relevant organizations such as health and social services, should be
personally contacted and the purposes and procedures explained to them. In the
case of health services it may be valuable to gain the support of senior medical 
and nursing staff. Professional groups can be somewhat protective of their own
discipline and not easily influenced by the need for additional requirements on 
their staff. However, without their support it will be difficult to move to the
implementation phase.
Where possible, official sanction should be sought that can then be used to assist
in the implementation process.
The organization responsible for introduction and implementation of a TDI should
be aware of political constraints that may arise when social data are published at
the national or international level. 
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2. Identifying stakeholders
Stakeholders’ needs will vary according to their area of work. Some will be concerned
with evaluation and performance, some will be most concerned with clinical impli-
cations, while others will be more concerned with issues of epidemiology and research. 
It will be important to attempt to balance these various needs through open and
realistic discussion about the potential for, and limitations of, the proposed new
information system.
All stakeholders should be identified and their expectations of the new system
should be managed and realistic. Experience shows that unrealistic expectations lead
to dissatisfaction and rapid decline in data contributions.
Motivation will contribute strongly to achieving successful implementation. In order
to encourage the key parties in the field to participate, it is important to motivate
them towards the objectives and necessity of data collection. 
Most importantly, clear information about the use of the data at all levels is impor-
tant in order to get parties to cooperate during implementation of the information
system and for its persistence.
3. Location
The organization responsible for implementation, data collection, analysis and man-
agement should be identified early. It is often sensible to appoint an organization
that will act as objective collector and processor of the data. The organization must
be in close contact with the treatment facilities and related organizations that have
to supply the data and should be steered by the persons in charge of this policy
area within the Government. Clear agreements should be made in relation to the
expected scope and activity of the organization, including roles and responsibilities
concerning such things as data protection/privacy, quality control and feedback.
One option may be for the “lead organization” to be one of the treatment organi-
zations themselves, in particular in the early stages of development. This situation
would need to be very carefully handled so as to maintain data integrity and per-
ceived impartiality. In this case it would usually be important to agree on a plan to
hand over the operation of the information system to an independent third party
when fully operational.
4. Funding
Adequate funding and accountability should be established for the whole project.
Resources should be made available for all operational aspects as well as for train-
ing at the central and peripheral levels. Resources may also need to be provided to
contributing agencies in order to facilitate the data collection and upload/download
processes. 
13
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C. Inventory of services and description of the treatment system
In order to be able to interpret the data properly, an overview of all treatment organi-
zations and the services they provide within a country is indispensable. This is a
far from trivial task and a classification structure appropriate for the treatment
system will need to be developed or adapted. It should cover the widest range of
treatment facilities and helping organizations that engage with drug misusers. This
overview will help to identify issues of coverage and reliability. It also allows for
stratification of data according to the specific nature and content of the available
treatments and services.
D. Ethical issues
Four general ethical principles of research/information-gathering on human subjects
pertain:
(a) Autonomy;
(b) Beneficence;
(c) Non-maleficence;
(d) Justice.
The principle of autonomy is better known as informed consent. Informed consent
comprises three components: information, understanding and consent. It should be
given without external pressure and without unreasonable inducements. It is ideal
if a neutral party obtains consent rather than the main treatment provider. Non-
participation or withdrawal of consent should not result in disadvantage for the
client. Consent is not required if the data are already in the public domain, but the
definition of “public domain” varies from country to country. It is not necessarily
the case in each country that informed consent will be required for the collection
and collation of routine anonymized treatment data.
The principles of beneficence (do good) and non-maleficence (do no harm) are
often combined. The ultimate aim of epidemiological research is to increase peoples’
opportunities to choose options that enhance their health. There is also a moral
obligation to cause “no harm” to those who participate in research studies or
surveillance systems. The risk of harm associated with an epidemiological surveil-
lance system is low, although breach of an individual’s privacy is a risk. Data stored
in a surveillance system should only have personal identifiers if absolutely neces-
sary and access to databases should be restricted to a “need-to-know” basis. The
storage of, and access to, identifiable data should follow procedures that prevent
disclosure. When analysing the data pertaining to small numbers of subjects, care
should be taken in case an individual can be identified. People who participate in
a surveillance system should be presented with summary reports on a regular basis.
The reports need to be disseminated in an easy-to-assimilate format (such as a
newsletter) and can be used by participants for advocacy purposes. 
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A conflict of interest (justice) arises when the researcher or sponsor has or appears
to have a vested interest that may influence the interpretation of the results. Prior
to implementing a surveillance system, the lead team should identify possible con-
flicts of interest and implement strategies to deal with them. Conflicts of interest
are more commonly associated with industry- and government-sponsored research.
All results are the intellectual property right of the parent organization and their
independence must be maintained at all times. Prior to publication, it is good prac-
tice to ensure that results are peer-reviewed by at least one independent expert. The
results should be released to the media and public at the same time. 
A drug treatment reporting system requires a protocol and its primary objectives are:
(a) To state the current situation and justify the need for the proposed reporting
system and outline its potential outcomes;
(b) To establish the appropriateness and validity of the proposed methods;
(c) To demonstrate the feasibility considering staff and client participation, as well
as training and resource requirements;
(d) To confirm that the principal investigator has the capability to implement the
system successfully.
The protocol will be used to obtain permission and resources as well as to guide
the implementation of the surveillance system. It will be a key document when eval-
uating the validity and usefulness of such a system. 
In order to comply with ethical considerations, it is necessary to write a detailed
study protocol outlining the current situation and rationale for the proposed
reporting system. This protocol will present:
 The objectives of the drug treatment reporting system;
 The methods employed to collect, enter, store, validate and analyse the data;
 Data protection issues pertaining to the specific country and procedures to
address them;
 Ethical considerations (consent, confidentiality and use of data) and the actions
taken to address each of them (such as client and service provider information
forms, procedures to store and access data, procedures to review pending
publications);
 The implementation plan, justifying human and financial resources and structures;
 The outputs expected from the reporting system.
E. Technical standards
Data transfer and supply should meet the required safety standards for such sensi-
tive files. This may entail file protection measures, line security, access security, user
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authorization and similar (sending protocols, hash totals, encryption, decryption,
virtual private network (VPN) and public key infrastructure (PKI).
Choices have to be made within the technical and legal possibilities available in a
country. A framework for standardizing security can be found in:
International and national standards in healthcare information security
International Standards Organization
The International Standards Organization (ISO) work on information security and
the relation to healthcare can be best described with the following scheme:
ISO roadmap
Requirements  Guidelines  Specific standards 
Integral security Risk assessment Banking
Management system Risk treatment Health care (ISO 27799)
(ISMS)BS17799.2 Quality assurance (ISO 17799)
European Standards Organization 
The European Standards Organization (CEN) and ISO agreed to exchange work
items in order to propel the convergence of European and worldwide standards. This
agreement is known as the Vienna Agreement. CEN/TC 251 is responsible for 
the topic “healthcare informatics”. Important (pre-)standards are ENV13606 (Elec-
tronic healthcare record communication) and ENV13608 (Security for healthcare
communication).
In addition, national standardization commissions exist in many countries that make
implementation protocols for international standardization.
F. Security management
Information security has multiple dimensions. When collecting national information
on treatment demand the focus is on three of these: 
1. Privacy enhancing technology 
The collection of drug treatment information should be protected by a pseudo-
anonymization procedure. Personal identifiable information should be encrypted 
with a one-way algorithm in order to prevent linkage of information to identifiable
persons. 
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2. Transport security
Message encryption is used during transport of the data to a national database. A
simple encryption procedure as a password-protected WinZip© file may be sufficient
if the data have already been subjected to the encryption algorithm and cannot be
used to trace identifiable individuals.
3. Storage security
Special protocols should be established and hardware/software solutions imple-
mented to prevent illegal remote and local access to terminals with a connection to
the treatment data. 
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A. Introduction
Many countries have already developed national data collection on
the activities and characteristics of drug and/or alcohol treatment
services and their clients. 
In order to aggregate and compare such data across nations it is neces-
sary to identify a core set of common data items and to harmonize
methodologies of data collection. The complexity of such an endeavour
should not be underestimated. Although it may be relatively easy to
derive a brief item list, the task of harmonizing the scope of collections
and achieving consensus on a basic set of definitions, such as what
constitutes treatment and drug use, is considerably more challenging. 
In the development of this Toolkit, a comparison of several national
and provincial minimum data collections on treatment supply indi-
cators from treatment services was undertaken in order to identify a
common set of data items. The Treatment Episode Data Set (TEDS)
of the United States of America, the European TDI, the Australian
National Minimum Data Set (NMDS) and data sets from Canada and
Southern Africa were chosen for the comparison. It should be noted
that the European TDI is itself derived from the experience of several
established European systems and follows also the experience of the
Pompidou Group [43, 44].
Common items forming the basis of a core data set relate to client
characteristics, treatment characteristics and patterns of drug use.
Major differences between the collections include the unit of measure-
ment, for example, client registration (European Union), treatment
registration (United States) or treatment episode (Australia); report-
ing rules and time-points for data collection. These systems also differ
in the range of agencies, clients, activities and drugs included in the
data collection. The similarities and differences between these and
other data collection systems are not presented here. Instead, this
Toolkit limits itself to the key practical issues that would need to be
addressed in order for an internationally consistent data set to be
derived.
B. Guiding principles
The least burden possible should be placed on treatment service staff who will be
responsible for collecting the data. This may be achieved if the following are
observed:
 Every attempt should be made to utilize, and/or adapt, pre-existing data
collection systems. Countries with data collection systems already in place will
be more amenable to participating in an international collection if the data can
be extracted from their systems without the need for fundamental changes in
scope, definitions or item list.
 Countries lacking a data collection system can be provided with a template for
items and methodologies of collection, one that is modest but has the capacity
to be expanded upon to suit local requirements for data.
 Consideration should be given to how data are routinely collected at the treat-
ment centres in order to ensure that: (a) wherever possible, duplication of data
collection is avoided and (b) both the process of data collection and the data
itself are clinically useful, and every attempt is made to integrate data collection
into routine clinical practice.
 Differences in scope and definitions should, within reason, be able to be accom-
modated as long as they are clearly identified and documented.
Additional considerations:
 Collection should focus on a limited number of indicators and a manageable
core data set.
 Data should be collected in accordance with sound scientific methodological
principles to ensure reliability and validity.
 Collection methods need to be adaptable and sensitive to different cultures and
contexts while retaining consistency.
 Item and concept definitions should be standardized, along with the scope of
collection and reporting period.
 Data collection and reporting processes should be ethical and ensure that the
client’s confidentiality and privacy is protected.
 Data collection should be feasible and cost-effective.
 The roles and responsibilities of both the organization and the individuals
working within it should be clearly identified, understood and accepted.
 Contact must be established and maintained with agencies to promote
compliance and assist with local implementation issues.
 Support needs to be engendered at all levels of service administration and
delivery.
 Feedback must be provided in a timely fashion to agencies collecting the data
and at the local, regional and national administrative levels.
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C. Recommended core international data set
Based on the review of key international information systems noted earlier, there is
now widespread agreement over the core essential data categories that are desirable
in order to build a useful, reliable and comparable system. These are presented in
summary form in the table below. It is envisaged that this set of items could
potentially form the basis of a core international data set. 
Core item set derived from comparison of data sets
Client Drug use (last 30 days) Treatment
 Attributora  Primary drug  Treatment centre type
 Age/date of birth  Secondary drugs  Date of treatment start
 Gender  Method of useb  Source of referral
 Race/ethnicity  Frequency of useb  Prior treatment episodes
 Living status  Age of first useb
 Employment status
aAttributor (initials + date of birth + gender), or equivalent method, to minimize multiple counts.
bFor primary drug or each drug, if possible.
These items should be considered to be the “lowest common denominator” data
set. Adoption of this data set would place a minimal (or no) extra burden on
countries that are presently collecting national treatment data and provide a modest
set of items for collection in countries without existing systems. 
It should be noted that there will always be contextual differences between nation-
al approaches to problems of drug misuse, including whether treatment services are
led primarily by medical, social or legal constraints, and it is important to be sensitive
to these and other national/local issues.
D. Unit of measurement, concept and item definition
Apart from deriving a set of items for the core collection it is necessary to decide
upon the unit of measurement for the data collection, for example, whether it is to
be based on client registration or treatment episode. Secondly, a consensus is required
on definitions of essential concepts, such as what constitutes “treatment”, when
treatment is said to commence, what is the definition of “client” and what is meant
by “drug use”? Lastly, the items should be defined and their data fields, if not
harmonized exactly, need to be able to be mapped to a common set of codes. Such
crosswalk methodology can be outlined in a data dictionary. This would be the
subject of later development. The key to success in international collection is to
ensure that data collected from different countries can be crosswalked to a common
set of acceptable codes. 
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While there is no clear agreement on the meaning of all concepts/definitions across
countries, and there will be many variations globally, if a country is just starting
out, the recommendations below may act as a useful guide.
1. Unit of measurement
The most pragmatic approach is to adopt client/case registration as the most basic
unit of measurement in a manner similar to that currently used in the TDI collected
in the European Union. That is:
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Client/case registration
A client/case is a person who starts treatment for their drug use in a treatment
centre during the calendar year, 1 January-31 December. 
In order to minimize multiple counts of clients attending several different agencies
within the same year, for the purpose of national TDI-type reporting, only the last
treatment provided to a client is counted in any year and treatments continuing
from previous years are not counted in the later years. This applies to any time peri-
od or geographical area chosen (see chapter VI, Analysis and reporting, and also
refer to the TDI, Standard protocol 2.0. (http://www.emcdda.eu.int/?nnodeid=1420
and link to the European Monitoring Centre for Drugs and Drug Addiction/Joint
Pompidou Group—EMCDDA Treatment demand indicator Standard protocol 2.0,
under “Protocol and methodological reports”)). Adopting this approach allows for
episode-based systems to be “mapped” and counted in equivalent terms to client-
based registrations. 
The choice between treatment episode and client/case registration: 
(a) Treatment episodes are generally regarded as being for the period from the
beginning of treatment (for a drug (or alcohol) problem) to the termination of
treatment (discharge). Establishing a discharge date is critical since, without
this, it is difficult to delineate the end of a treatment episode, short of defining
an arbitrary cut off point, for example, six months;
(b) Client/case registration is generally regarded as being from the point in time
when the client engages with a treatment service (see below). It should be
noted that client registration, at the individual level, underestimates the true
burden placed on the treatment system as it is known that clients can access
many services in the course of a year. A discharge date and reason for dis-
charge is a basic requirement for any move towards examining treatment out-
come. However, client/case registration provides a reasonably straightforward
start and can be upgraded to an episode-based system subsequent to initial
development. 
2. What is treatment?
As the scope and nature of treatments provided for people with drug problems vary
enormously between countries, it is important to adopt a sufficiently broad defini-
tion of treatment and its commencement that is interpretable and acceptable across
a wide area. 
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Drug treatment
Drug treatment is considered to be any structured intervention aimed specifically
at addressing a person’s drug use.
Although a drug user’s problems may be very wide ranging, treatment addresses a
person’s drug use itself. Examples include stabilization or reduction of drug use,
maintenance or abstinence regimes, behavioural therapy, medical or psychological
interventions and so on. In this context, help with related problems of housing,
education or relationships, for example, do not constitute treatment, even though
support in these areas may be important adjuncts to treatment.
3. What agencies should be included in the collection?
In many countries, specialized drug treatment facilities provide most of the treat-
ment places, although it should be noted that drug users will, of course, be seen in
a number of other generic contexts (e.g. at the family doctor’s) or other specialist
medical facilities (e.g. a psychiatric department). In countries where no specialist
drug facilities exist, problem drug users will often be seen primarily in general
medical and/or social help contexts. It is important to include all locations in which
drug users are treated in a structured intervention for their drug use.
Self-help groups such as Narcotics Anonymous or Alcoholics Anonymous are not
normally considered to constitute structured treatment and should therefore normally
be excluded.
Treatment centres
A treatment centre is any agency that provides treatment to people with drug
problems. Treatment usually takes place at specialized facilities for drug users,
but may sometimes occur in generic contexts such as general practice. One
treatment centre may provide more than one treatment programme or service. 
Treatment centres can be based within structures that are medical or non-medical,
governmental or non-governmental, public or private, specialized or non-specialized.
They include inpatient detoxification units, outpatient clinics, drug substitution pro-
grammes (maintenance or shorter-term, detoxification (or “detox”)), therapeutic
communities, counselling and advice centres, street agencies, crisis centres, drug
treatment programmes in prisons and special services for drug users provided 
within general health or social care facilities.
It should be noted that the following are usually excluded: hospital emergency rooms
or general health/social care facilities that drug misusers contact primarily for help
with problems other than with drugs and programmes concerned exclusively with
making syringes/needles available or disseminating information, unless these activi-
ties are part of a wider range of services offered to help people with drug problems.
4. When does treatment commence?
Some flexibility is required here to reflect different clinical practice. In some situa-
tions, clients are triaged prior to decisions being made about their treatment; in
others, client assessment represents the start of the treatment process; in yet others,
prescribing is considered to be the start of treatment. 
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Start of treatment
This is the first formalized service contact when assessment and/or treatment
occurs with the treatment provider and typically involves formal registration of
the person into the treatment centre. This includes structured assessment leading
towards a treatment plan.
5. Who are the clients?
Client definition
A client is a problem drug user who starts treatment for drug use at a treatment
centre. This excludes persons in contact with a treatment centre on behalf 
of drug users and persons with problems that relate only to their relationship to
a drug user.
The system should count as clients, only problem drug users in treatment and not
third-party clients (presenting on behalf of someone else) or those making enquiries
for advice and information alone. However, if the treatment information system is
already mandated to include such third-party clients, it is vital that the system is
capable of identifying these and excluding them from the analyses.
6. Which drugs are included?
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Drug definition
Any drug of misuse excluding alcohol or tobacco.
OR
All drugs of misuse, including alcohol and tobacco, as long as these can subse-
quently be excluded if necessary from further analyses.
The concept of drug misuse often excludes the use of alcohol and tobacco, even
though use of these may result in far greater health problems and burdens for society.
Cultural and societal issues influence the way in which drugs are viewed and
approached and vary from one country to another, as do the laws that make drugs
legal or illegal. The inclusion or exclusion of alcohol or tobacco from an informa-
tion system is largely a decision driven by policy and resources. There is no intrin-
sic reason why these drugs may not be included in data collection, even though it
should be noted that the questions in most drug treatment core item lists do not
specifically address alcohol or tobacco problems.
It is very important that all systems should be capable of excluding users of only
alcohol and tobacco from their data sets, so that international analyses and com-
parisons can be made between data sets.
The misuse of prescription drugs resulting in problems for an individual should
be included. 
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Once the implementation phase is reached, it is assumed that all
background work has been accomplished. Implementation is then
practical by nature.
Involving people
The cooperation of those to be involved in a drug data infor-
mation system is crucial to its success. Individuals must be
enabled to carry out their functions by means of support, train-
ing and resources. Three phases are necessary: identification,
development and field work.
A. Identification phase
It is suggested that the following be identified:
 Suppliers of information
 Host organization(s)
 Other key stakeholders
 Software/hardware needs 
 Lines of communication
 Lines of accountability
 Processes
 Training needs
 Feedback loops
B. Development phase
Alongside the above, or shortly after, a phase of development is
essential so that all materials and structural elements are in place
before attempting to start up the new system. This is particularly
important if confidence in the new system is to be built up from the start. Support
and cooperation, in particular from clinical treatment facilities, will very soon be
lost if the system is not clearly thought through and practically acceptable. It 
has often been found to be useful to carry out field testing of the instruments
(schedules, documentation, etc.) to ensure that they are understandable and correctly
interpreted.
It is suggested that the following be developed:
 Implementation plan and timescale
 Data capture/analysis software
 Data handbook and dictionary
 Written materials 
 Letters to stakeholders
 Publicity material
 Logos and so on
 Data collection sheets 
 Practical guidelines
 Protocols for data capture, delivery and feedback
 Training resources
 Pilot testing and revision
Where forms are used they should be designed to be simple, user-friendly and, prefer-
ably, one-page instruments. It is most important to be relatively modest at first and
not try to collect everything that might eventually be needed. There is a need for
pragmatism and realism.
Policy and procedures should be published as a manual. This acts as an instruction
manual for those implementing a system for the first time and a subsequent check
for those who have a system already running. The manual should include at least
the following:
 Data submission (paper/disks/electronic/web-based)
 Deadlines and incentive/enforcement practices
 Data entry, including logical checks
 Feedback loop back to treatment facilities to report on, and correct, errors and
inconsistencies
 Data analysis plan (with dummy tables)
 Tailored, multi-level reporting plan
 Summary of ethical and security issues and how they are being handled
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C. Fieldwork phase
A programme of initiation and training should be implemented. All key stakeholders
should be contacted in person, either by letter or face to face, and considerable
efforts made to ensure full understanding and support for the initiative. Adequate
time should be allocated to this exercise.
These initial contacts should be followed up by regular contact with treatment facil-
ities and key stakeholders, including visits, phone calls, newsletters and so on. This
is helpful in order to encourage attention to detail and quality control in data
capture, as well as to receive feedback on operability, clarity, data volume and other
identified issues.
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A. Introduction
In order to convert collected data into useful feedback it is necessary
to prepare the data for analysis and to decide appropriate forms of
feedback for the audiences concerned. Data will need to be cleaned
and validated, appropriate software employed, reporting priorities
selected, case definitions clarified and appropriate levels of reporting
detail agreed.
1. Audience
Treatment demand indicators should provide multiple levels of feed-
back appropriate to different audiences. These are likely to include
provider services, commissioning organizations, national government
bodies and, where appropriate, international organizations. Reporting
to existing international systems may have established procedures to
be adhered to. In some instances it may be appropriate to adhere to
the same methods as those used for international reporting, but to
tailor analysis to specific and local needs in others. The rest of this
chapter will concentrate on a common range of options that will face
anyone needing to analyse a drug treatment data set.
2. Case definitions
A treatment demand indicator is not designed to measure the full
extent of activity between drug services and their clients. Within a
single service over a particular time period, an individual client may
experience multiple episodes and multiple modalities, or treatment
regimes, within those episodes. In the same time period a client may
also, of course, make treatment demands at more than one centre. A
separate episode may be recorded each time an individual presents
to a centre. For each aspect of reporting a decision needs to be made
as to whether the individual or the episode is the most appropriate
basis for analysis. Once this decision has been made, careful consid-
eration should be given as to how to define and extract data about
the individual or episode from the available dataset.
Individuals
It is general practice to report on client characteristics (such as gender, ethnicity,
age and drug use) at the level of the individual. That is, only one case for each
individual within the appropriate time period is used for analysis. On this basis a
systematic prioritization of cases must be employed. The options for this are 
listed below:
(a) Earliest episode within the time period;
(b) Latest episode within the time period;
(c) Aggregation of each episode into a single case (only appropriate for certain fields)
It is generally considered most appropriate to report on the latest case for an indi-
vidual within a time period as this represents the most up-to-date report of that
client’s status and activity. Client details such as living status, employment status
and drug use may of course change over time and the most recent status is likely
to be the most appropriate. Whichever method is adopted, the limitations must be
made clear to the data recipient so as to avoid misinterpretation.
Consider, for example, a group of 10 clients who make a treatment demand early
in the reporting period with a primary heroin problem. Five of these clients also
seek treatment a second time, later in the period, with a primary cannabis problem.
The “latest episode” methodology will report five individuals with primary heroin
problems and five individuals with primary cannabis problems. Another method of
reporting (aggregation of cases) would report that 10 individuals reported a primary
heroin problem and five reported a primary cannabis problem, but that the two
groups are not mutually exclusive. A national demand indicator will clearly involve
a much greater degree of complexity, but this simple example shows how important
it is to consider which method of interpretation of the data is appropriate. 
Age will of course change over individual episodes and with the likely interest and
emphasis on reports made by the young, there will be circumstances in which it is
the characteristics displayed at the earliest episode by an individual that will be
considered the most appropriate to consider. Similarly, if researchers are interested
in newly emerging drug use, the earlier episode in a time period may be of most
interest, in particular if the client is new, at this point, to the treatment system.
A mixture of these methodologies may be appropriate for specific contexts/
audiences, though it is generally recommended that, for clarity and ease of inter-
pretation, a single method is employed throughout a single report. Any deviation
from a standard methodology should always be accompanied by very clear guidance
and explanation.
For those characteristics which do not generally change (gender, ethnicity), it is pos-
sible to populate missing data from other cases by selecting the latest valid response
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to the field, or variable, from within the time period. For example, if the “latest
episode” methodology is employed and gender is missing but present in the pre-
vious episode, then the information may be imported from the previous episode.
Even where the field/variable may legitimately change, it is often still valid to select
the latest positive response in cases of missing data.
Episodes
Treatment episode characteristics, such as the type of agency or source of referral,
may be more usefully reported on at the episode level. Again, there is more than
one way of interpreting these data; at the treatment centre level it is often more
appropriate to represent the totality of demand rather than just the number of
individual clients.
B. Data preparation
Good analysis starts with a thorough routine of data cleaning and validation. This
is likely to involve identifying erroneous, or potentially erroneous, data and seeking
to confirm/edit the data or to delete the appropriate case(s). The computer system
for data entry may not allow a case to be entered if any key fields are missing 
(so-called “internal validation”). If this is not the case, then missing items need to
be identified before any analysis can begin. Some other common checks may include
the following:
 Age too high or too low
 Route of administration not compatible with drug (e.g. cannabis; inject)
 Age of first use greater than current age
Depending on the data collected there may be hundreds of such internal validation
checks. These can absorb a considerable amount of time between data collection
and reporting, especially where agencies need to be contacted to correct the data
provided. Therefore, it is vital to implement a consistent and automated/semi-auto-
mated system of data validation for the attention of data-processing staff.
1. Recoding categories
It is best to collect data with a high level of detail, but to recode those data into
manageable categories for the purposes of much reporting. For example, several
hundred individual drug categories may be recorded at source that will need recoding
into groups for any manageable level of reporting. These groups can be as broad or
specific as required, for example, opiates/stimulants or heroin/methadone/other opi-
ates/cocaine/amphetamine/other stimulants. Categories should be flexible enough
to change over time in order to reflect changes within the reported population. An
example of this would be the emergence of crack cocaine as a separate category 
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to “cocaine” as a result of its growth in use in the United Kingdom of Great Britain
and Northern Ireland throughout the 1990s. It will still be essential to analyse drug
use at the smallest possible level of detail in order to monitor the use of very 
specific drugs.
Age groups will also need to be created for ease of reporting and these should be
split into categories of five years to allow for classification that accords with 
country needs and is flexible enough to allow recoding for comparison with other
international data.
In recoding specific data into broader groups it should always be possible to “reverse
engineer” the process so as not to lose any detail in the available data.
2. Calculation of key fields
In many databases age is not collected, but rather calculated from date of birth. For
a treatment demand indicator, age should be calculated as the time between date
of birth and date of treatment demand. This provides a greater level of accuracy
than simply collecting age in the original data. It is reliant on both date of birth
and date of treatment demand being present, although without these it would be
impossible to define an individual (based on attributor) within a time period.
C. Data analyses and reporting
1. Suggested analyses
Chapter II gives a good indication of the depth of uses of a treatment demand indi-
cator, especially ones established over many years. The total scope of possible
analyses is too great to cover here, but certain fundamental reporting needs are
likely to be held in common by different countries. Clearly the central role of a TDI
will be to report on the nature and extent of drug use that is reported to treatment
agencies alongside an assessment of how these demands differ between subsets of
client characteristics. A bare minimum of reporting (for each time period and area
of residence or treatment provision) should include:
(a) The number of individuals making treatment demands: probably the most
central figure to any TDI, indicating the number of people who both match
the criteria of problem drug user and have sought treatment for their problem;
(b) The number of treatment demands made by those individuals: many individu-
als make multiple demands over time and across services or service provision
areas, and this figure describes the level of demands made of those services;
(c) The types of agency to which demands are made: as services are commissioned
to meet need, it is essential to understand the level of demand made to each
service type and the nature of the problems presented to them;
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(d) The numbers reporting primary use of each drug: the primary drug of use can
be the drug causing the most problems at the point of making a treatment
demand and/or the drug for which the client sought treatment (its exact defi-
nition is a training issue for participating agencies). Either way it is the clearest
indication of the nature of the problems being presented to which services need
to respond;
(e) The numbers reporting any use of each drug: drugs other than the primary
drug of use may or may not be problematic in their use. As such, although
they may not be such a direct indicator of the nature of demands made to
services, they are still a vital indicator of wider drug use and potential unmet
need;
(f) Levels of injecting: the injecting of drugs can both indicate the “advanced”
nature of an individual’s drugs use and create public health concerns regard-
ing the spread of blood-borne diseases. As such, “injecting” is a vital report-
ing indicator. Localized assessment of this factor can also provide a direct
indication of clean injecting equipment service provision needs;
(g) The number of individuals previously/not previously treated: this allows for the
monitoring of the level of demand made by the (previously) hidden population
and can indicate any emerging trends in drug use and client characteristics. It
may eventually be used to indicate epidemics or stable populations (see 
chapter II);
(h) The gender of reported individuals: males and females may have a different
range of problems, have different service needs and present to services at dif-
ferent ages and to differing degrees. All these factors represent important
reporting needs;
(i) The ethnicity of reported individuals: ethnicity is a similar case to gender 
representing a window into monitoring the equity of service provision within
diverse communities;
(j) The age groups of reported individuals: younger individuals may have different
treatment needs and any difference in the nature of their treatment demands
may indicate emerging trends.
This list is far from exhaustive as any number of combinations of reported data may
be required by different key stakeholders at different times. Indeed it is a general
principle that all data collected should be utilized and reported at some stage if 
it is justifiable that it is collected in the first place. However, it is essential to
formulate consistent and standardized reporting that can be compared over time
and expanded upon as appropriate. The above list provides for an assessment 
of the nature and levels of demand and how these may change over time. Descrip-
tors (a)—(f) above should be analysed by age, gender, ethnicity, whether previously
treated and area of residence/treatment in order to provide for the most obvious
and needed comparisons. The majority of basic information requirements and
monitoring towards targets is likely to be provided within this minimal reporting
system.
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2. Trends
It will be important to record and report on changes in these basic descriptors over
time. This can be used to assess changes in the nature and extent of demands and
their progress towards any set targets. It is most common to report on changes
between annual periods. Changes over shorter periods can be assessed, although these
may be particularly subject to seasonal changes or other short-term fluctuations. For
commissioning purposes, it is generally desirable to be able to analyse data on the
basis of fiscal (financial) periods, usually 1 April to 31 March. However, reporting
systems should be equipped to report over both calendar years and fiscal years. 
Caution should be taken not to simply compare one period of data with the pre-
vious one without assessing the significance of these changes within the context of
longer-term trends.
3. Area of treatment provision and client residence
Commissioning bodies are likely to need to know both about the level of treatment
demands within their area and the level of treatment demands made by residents
of their area, as the two are unlikely to be identical. Analyses may need to be
reported at either one of these levels and may also need to describe the amount of
crossover between the two. 
4. Levels of interpretation
It is usually beneficial to include some level of interpretation of the analysed data
in any report. Inclusion of appropriate interpretation is likely to improve any feed-
back report as it can provide a commentary on, and insight into, the descriptive fre-
quency data tables. At the national and regional levels, this may involve comparisons
between administrative or commissioning areas whereas reporting at the local, or
even at the individual agency level, may involve issues of specific and detailed local
interest.
Whenever data are interpreted, care should be taken to consider the potential influ-
ence of bias that may be introduced by issues of coverage. If, for example, particu-
lar sub-populations have declined to participate in data collection because of issues
of informed consent, or if particular significant treatment centres have not parti-
cipated, this will affect the total data captured by the system and available for
analysis and interpretation.
5. Anonymity 
Reporting from a TDI should be conducted at a number of levels, most commonly
at the national, regional, commissioning area and agency levels. Though all reports
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at a level above that of the agency should be in summary, aggregated format with-
out client identification, care should still be taken over potential identification when
reporting on a small number of cases, especially if the reports are to be publicly
available. All reporting should be useful and fair and should never jeopardize the
anonymity of the client, or present an impression that anonymity is not taken
extremely seriously. Reporting on the drug use of a small number of clients with
certain characteristics within a certain area of residence, although not directly identi-
fiable, may be considered inappropriate. A general rule is to consider any reported
subgroup of less than 10 individuals to be inappropriate, although rules are not
internationally set on this and careful decisions must be made at the local level.
6. Caveats/limits of data 
All analyses and reports must be accompanied with clear descriptions of exactly
what the data can and cannot be legitimately interpreted to say. In particular, it
must be made clear that data relate to those individuals reporting problematic drug
use to treatment services and not to the whole drug using population, and that any
measure of new demands made to agencies does not represent the full extent of all
demands experienced by treatment services.
Changes in service provision may have a significant impact on the throughput of
certain groups of people, for example, the implementation of a service for a type of
drug use behaviour not formerly catered for. These changes in service provision may
result in proportional changes in characteristics of the treated population and should
therefore be interpreted in context, that is, they may reflect changes in the popu-
lation seeking treatment, rather than changes in the underlying problem drug-using
population.
7. Feedback/quality monitoring
It is essential to include within the feedback loop those agencies which provide the
source data both so as to give feedback analyses of their own data contribution and
to allow them to see how their contribution compares with others within appro-
priate geographical or commissioning areas. This also provides an excellent oppor-
tunity to report on levels of data completion and quality within provider agencies
and to place relevant stress on their importance.
Regular reports, at monthly or other intervals, of data derived from the system should
be provided to all key stakeholders, in particular contributory agencies/treatment
facilities. These may take the form of tables of data with or without detailed com-
mentary, according to need and the resources available. More detail and less com-
mentary may be more appropriate at the treatment facility level, with increasing
commentary and interpretation but fewer data tables at the area/regional or nation-
al/international level. Feedback to staff at the data capture level is also critical as
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a way of encouraging interest and motivation. Significant value must be returned to
agency staff if they are to make the effort to provide data in the first place.
8. Ad hoc requests
Systematic reporting structures cannot answer all the questions that the data may
raise. It is most likely that essential questions will be answered for the majority of
stakeholders but that further in-depth questioning will be needed by a significant
minority. It is, of course, difficult to predict the nature and level of these additional
requirements. However, it is wise to ensure that the analytical capacity exists to
deal with them when they arise. Caution should be taken to ensure that such ad
hoc requests do not interfere (in human resource terms) with the business of pro-
viding a standardized reporting system. Clear guidance must be provided in assess-
ing the appropriateness and priority of each request, bearing in mind that not all
forms of analysis should be made available to all who request them.
9. Handling missing cases
Missing data raises a number of issues, including the need to provide feedback to
agencies on the requirement for as complete a set of data about each individual as
possible and the need for caution in analysing and reporting data. If certain key
fields are missing, such as elements of the attributor (initials, date of birth, gender)
or reporting agency, then the case/record may need to be excluded from analyses
or even deleted if there is no chance of further completing that record.
Although some level of missing data is inevitable, the extent can affect the validity
of interpretation. The preferred method of handling missing data in tables of analy-
sis is to provide valid percentages (i.e. the number of valid responses as the denomi-
nator in calculations, not the total number of cases) and to report on the level of
missing data. This combination allows the reader to view percentages that total
100 per cent and to make some judgement on the extent to which they can be
taken as representing the population within the entire data set. 
10. Expanded data collection and analyses
This chapter has concentrated on some of the potential analyses of data from a
system designed to measure treatment demand. Some thought should also be given
to the possibilities that arise from a system capable of recording every treatment
episode and including start and end point data. Information of this quality can both
summarize treatment demand and provide a wealth of information such as the nature
and level of treatment actually received, the length of contact with services (includ-
ing levels of retention and attrition within episodes) and total client loads over any
time period/organizational area.
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It is valuable to update the inventory of service provision on a regu-
lar basis for inclusion in the reporting system. This can be achieved
through systematic and routine contact with all treatment facilities.
It may be most practical and useful to organize this on a regional or
other small area basis.
A logging system that monitors and acknowledges data arrival from
each source, alongside a record of data-processing queries and anom-
alies that derive from validation procedures and error checking, is
also useful. Difficulties at any level should be fully documented, as
should discussions held with contributors and other stakeholders.
Managerial issues that emerge should be included. A rolling pro-
gramme of contact and feedback to and from stakeholders should
be established. These may take the form of twice-yearly meetings of
key personnel, with peer update and review sessions and themed
expert input.
Evaluation is a continuous process that should identify gaps between
objectives and results. An evaluation of treatment demand indica-
tors/data should also aim: (a) to improve collected data; and (b) to
improve and revise the indicator, if necessary.
A. Internal validity
Checks should be made to ensure compliance to protocols and guide-
lines for data capture, data processing and data analysis. Internally
valid data will demonstrate correct case definition, correct use of
coding frames, avoidance or at least minimization of double counting
and acceptable levels of data completeness, avoiding extensive miss-
ing data values. Where data are missing and values (whether of text,
numeric or date fields) are out of acceptable range or inaccurately
coded, measures should be made to improve data quality.
It may be that practical improvements in data capture, for example,
improvements to data forms or provision of electronic data capture
via computer, will be necessary following review of operational methods and will
greatly improve data quality and validity.
Providing feedback reports to individual providers of the data that show outliers or
incorrect entries is one strategy to gradually improve data submissions over time. 
Some items of the database will need to be internally consistent. For example, dates
(birth, age of first use of drugs, date of start of treatment) should be sequential and
sensible, and certain items of drug data such as route of administration and whether
a drug is said to have ever been injected. 
Attributors
Many countries utilize the basic personal details of a person—that is, their names’
initials, date of birth and gender—to produce an attributor code that has sufficient
uniqueness without the practical possibility of real identification of the individual.
Commonly the first initial of the first name and the first initial of the last or family
name are used alongside the date of birth and gender, although considerable
variation is possible here according to country tradition.
The main purpose of such an attributor is to be able to link records and to mini-
mize duplication of records. This becomes very important when considering data
across years or even within years where it is possible that a person visits more than
one treatment service. For epidemiological purposes, although it is sometimes use-
ful to count episodes of care, in particular, for example, in work on performance
management, it is essential to be able to distinguish individuals—for example in
order to present valid percentages of users of heroin or numbers of males/females.
In order to do this, internal checks can be set up that identify exact matches and
that identify close matches. These are sometimes referred to as, “hard” and “soft”
matches. Ideally, close matches should be checked for accuracy, but in most cases
this will not be practical. There will be much variation across countries in the
possibilities and/or legality of such data matching and it is not the purpose of this
Toolkit to be proscriptive as to method. It is, however, important to be able to
distinguish individuals from repeat episodes within an acceptable level of error.
B. External validity
As most surveillance systems rely on self-report, it would be ideal to verify the data
by reference to external testing, such as urine analysis, saliva analysis or analysis
of hair. However, this is more likely to be the subject of research rather than
surveillance. Therefore most systems rely on other recorded indicators, such as
population surveys, mortality indicators, emergency room information and local intel-
ligence. Feedback from treatment services themselves is perhaps the best and most
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straightforward method of verification. For this purpose it may be useful to com-
pare cases reported to the indicator with cases selected from a sample of clinical
records from the treatment centres. In this way it is possible to check the centre
and client coverage over a period of time, as well as case definition and the methodo-
logical guidelines, and thus provide evidence for the sensitivity, specificity and
predictive capability of the indicator.
Contextual and qualitative information is also important to better understand and
interpret treatment data. Gathering relevant information about service availability,
accessibility, use and characteristics can support the external validation.
The issue of completeness of data capture, that is, to what extent all expected indi-
viduals are recorded by the system, is also important, as is the coverage of treat-
ment facilities themselves.
A cycle of maintenance and evaluation should be established to monitor all such
issues of data quality and validation, and regular reports back to all key stakeholders
should be made available. In this way the data will be seen to be of increasing value,
and confidence will be built up that will enable proper utilization of the data in
decision-making processes that improve service provision and community responses
to issues of drug misuse.
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